Trial Profile
A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Pharmacodynamics
- Acronyms PREPARE
- 17 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 21 Oct 2021 Status changed from recruiting to active, no longer recruiting.